GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emmessar Biotech And Nutrition Ltd (BOM:524768) » Definitions » Return-on-Tangible-Equity

Emmessar Biotech And Nutrition (BOM:524768) Return-on-Tangible-Equity : -3.57% (As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is Emmessar Biotech And Nutrition Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Emmessar Biotech And Nutrition's annualized net income for the quarter that ended in Mar. 2025 was ₹-2.75 Mil. Emmessar Biotech And Nutrition's average shareholder tangible equity for the quarter that ended in Mar. 2025 was ₹77.08 Mil. Therefore, Emmessar Biotech And Nutrition's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was -3.57%.

The historical rank and industry rank for Emmessar Biotech And Nutrition's Return-on-Tangible-Equity or its related term are showing as below:

BOM:524768' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -40.75   Med: 12.84   Max: 79.27
Current: 4.14

During the past 13 years, Emmessar Biotech And Nutrition's highest Return-on-Tangible-Equity was 79.27%. The lowest was -40.75%. And the median was 12.84%.

BOM:524768's Return-on-Tangible-Equity is ranked worse than
59.36% of 903 companies
in the Drug Manufacturers industry
Industry Median: 6.7 vs BOM:524768: 4.14

Emmessar Biotech And Nutrition Return-on-Tangible-Equity Historical Data

The historical data trend for Emmessar Biotech And Nutrition's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmessar Biotech And Nutrition Return-on-Tangible-Equity Chart

Emmessar Biotech And Nutrition Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.10 8.01 7.85 9.26 4.18

Emmessar Biotech And Nutrition Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.59 4.81 14.34 0.89 -3.57

Competitive Comparison of Emmessar Biotech And Nutrition's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Emmessar Biotech And Nutrition's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmessar Biotech And Nutrition's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emmessar Biotech And Nutrition's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Emmessar Biotech And Nutrition's Return-on-Tangible-Equity falls into.


;
;

Emmessar Biotech And Nutrition Return-on-Tangible-Equity Calculation

Emmessar Biotech And Nutrition's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=3.161/( (74.024+77.08 )/ 2 )
=3.161/75.552
=4.18 %

Emmessar Biotech And Nutrition's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-2.748/( (0+77.08)/ 1 )
=-2.748/77.08
=-3.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Emmessar Biotech And Nutrition  (BOM:524768) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Emmessar Biotech And Nutrition Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Emmessar Biotech And Nutrition's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmessar Biotech And Nutrition Business Description

Traded in Other Exchanges
N/A
Address
38, Cawasji Patel Street, 29, Kamer Building, 4th floor, Fort, Mumbai, MH, IND, 400001
Emmessar Biotech And Nutrition Ltd is a healthcare company. The company is engaged in the manufacturing and marketing of fine chemicals products, and healthcare and nutritional products. The company caters to patients with obstinate skin problems, muscle problems, bone problems, and other debilitating chronic physical ailments. The business segments of the company are Healthcare, Fine Chemicals, and Rent on Immovable property of which the majority of the revenue is derived from the Rent on Lease land segment.

Emmessar Biotech And Nutrition Headlines

No Headlines